Metabolic bariatric surgery

Metabolic bariatric surgery has been studied in 27 papers since 2024: 11 observational studies in people, 14 reviews; 20 in the past year. The newest paper, Nov 20, 2026: “Title: Outcomes of metabolic bariatric surgery in obese CKD patients: A MBSAQIP analysis”.

Intervention

27 papers study it38 findingsUpdated

9 new papers in 30 daysSee all 27 papers on metabolic bariatric surgery

At a glance

Metabolic bariatric surgery is linked with fewer cardiovascular events in humans, with independent replication, and with lower mortality in people with obesity and type 2 diabetes compared with obesity management medications. A postoperative study finds no clear link with kidney-cell senescence. Some papers declare ties to companies including Medtronic, Eli Lilly and Novo Nordisk.

38 findings in 19 papers from 2024 to 2026, 10 of them since June 2026

Independent labs found the same change in people. 12 independent labs in 7 countries.

“Compared with OMMs, MBS was associated with lower 5-year cumulative incidences of nephropathy”
Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patientsThe British journal of surgery2026doi:10.1093/bjs/znag139

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 12 independent labs in 7 countries
  • Funders: Ministerstwo Edukacji i Nauki and others
  • 9 of 31 findings with company ties
  • Humans11
  • In silico2

Studies in people

1 study gave metabolic bariatric surgery to people and measured what changed.

What changedDesignPeopleSource

up: Increases total body weight loss

Review of trialsadultsHigher degrees of obesityDiabetes, obesity & metabolism, Oct 20, 2025

What did studies of metabolic bariatric surgery find?

19

Studies of metabolic bariatric surgery measured 19 outcomes, among them body weight, obesity and HbA1c.

Body weight

downin humans2

2 studies
  1. Metabolic bariatric surgery decreases body weight in humans (selected patients with obesity).

    Reviewselected patients with obesity

  2. Metabolic bariatric surgery decreases body weight in humans.

    Review

Obesity

downin humans1

1 study
  1. Metabolic bariatric surgery decreases obesity in humans.

    Reviewlong-term

More on Obesity

HbA1c

no changein humans1

1 study
  1. Metabolic bariatric surgery showed no clear effect on HbA1c in humans (obesity; overall analysis compared with glp-1 receptor agonists) (SMD 0.03%; 95% CI -0.14, 0.20).

    Reviewobesity; overall analysis compared with glp-1 receptor agonistsn = 15,594

More on HbA1c

Body mass index

downin humans1

1 study
  1. Metabolic bariatric surgery decreases body mass index in humans (obesity; compared with glp-1 receptor agonists) (SMD 1.61 kg/m2; 95% CI 1.04, 2.18).

    Reviewobesity; compared with glp-1 receptor agonistsn = 15,594

Medical savings

upin silico1

1 study
  1. Metabolic bariatric surgery increases medical savings in silico ($12,001 cumulative medical savings per person).

    In silicocommercially insured adults with obesity without preexisting diabetes or cardiovascular disease5 years

Body mass index

downin humans1

1 study
  1. Metabolic bariatric surgery is linked with lower body mass index in humans (compared with GLP-1 receptor agonists) (mean difference -9.89 (95% CI -9.64 to -10.34)).

    Humanscompared with GLP-1 receptor agonists

More on Body mass index

Total body weight loss percentage

upin humans1

1 study
  1. Metabolic bariatric surgery increases total body weight loss percentage in humans (obesity).

    Reviewobesitylong term

Ongoing costs

downin humans1

1 study
  1. Metabolic bariatric surgery is linked with lower ongoing costs in humans (class II or III obesity, compared with GLP-1 receptor agonists) ($51,794 vs $63,483 mean total costs over 2 years).

    Humansclass II or III obesity, compared with GLP-1 receptor agonists2 years

Total weight loss

upin humans1

1 study
  1. Metabolic bariatric surgery is linked with higher total weight loss in humans (class II or III obesity, compared with GLP-1 receptor agonists) (28.3% vs 10.3% total weight loss).

    Humansclass II or III obesity, compared with GLP-1 receptor agonists

Total body weight loss

upin humans1

1 study
  1. Metabolic bariatric surgery increases total body weight loss in humans (higher degrees of obesity; superior to other treatments except LAGB and GCP).

    Human trialhigher degrees of obesity; superior to other treatments except LAGB and GCP

All 19

What is metabolic bariatric surgery linked with?

16

Studies link metabolic bariatric surgery with 16 measures, among them body weight, major adverse cardiovascular events and esophageal, gastric, pancreatic and prostate cancer incidence.

Body weight

downin humans2

2 studies
  1. Metabolic bariatric surgery is associated with body weight in humans (Patients with renal insufficiency, dialysis dependence, and controls) (>10% total weight loss achieved by 74% of RI, 80% of DD, and 85% of controls).

    HumansPatients with renal insufficiency, dialysis dependence, and controls6 months

  2. Metabolic bariatric surgery is associated with body weight in humans (type 1 diabetes and obesity) (29.7% total weight loss (IQR 29.4–30.3)).

    Humanstype 1 diabetes and obesity1 yearn = 162

Major adverse cardiovascular events

downin humans2HR 0.78

2 studies
  1. Metabolic bariatric surgery is associated with major adverse cardiovascular events in humans (Obesity and type 2 diabetes; compared with obesity management medications) (6.1% versus 8.1%; -2.0 percentage points; HR 0.78 (95% CI 0.73–0.84)).

    HumansObesity and type 2 diabetes; compared with obesity management medications5 yearsn = 379,858

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery
  2. Metabolic bariatric surgery lowers the risk of major adverse cardiovascular events in humans (RR 1.41; 95% CI 1.11, 1.78).

    Reviewobesity; compared with glp-1 receptor agonists; reported RR orientation is unspecified despite the stated lower risk with surgeryn = 15,594

Esophageal, gastric, pancreatic and prostate cancer incidence

mixedin humans1

1 study
  1. Metabolic bariatric surgery is associated with esophageal, gastric, pancreatic and prostate cancer incidence in humans.

    Review

Obesity-associated cancer incidence

downin humans1

1 study
  1. Metabolic bariatric surgery is associated with obesity-associated cancer incidence in humans (20–35% lower incidence).

    Review

HbA1c <6.5% attainment

upin humans1

1 study
  1. Metabolic bariatric surgery is associated with HbA1c <6.5% attainment in humans (76.7% versus 47.2%; P < 0.001).

    HumansObesity and type 2 diabetes with baseline HbA1c ≥6.5%; compared with obesity management medications1 year

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery

More on HbA1c <6.5% attainment

Percentage total weight loss

upin humans1

1 study
  1. Metabolic bariatric surgery is associated with percentage total weight loss in humans (Obesity and type 2 diabetes; compared with obesity management medications) (25.4% (95% CI 25.3–25.5%) versus 6.4% (95% CI 6.3–6.5%)).

    HumansObesity and type 2 diabetes; compared with obesity management medications1 yearn = 379,858

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery

Mortality

downin humans1HR 0.61

1 study
  1. Metabolic bariatric surgery is associated with mortality in humans (Obesity and type 2 diabetes; compared with obesity management medications) (2.1% versus 3.7%; -1.6 percentage points; HR 0.61 (95% CI 0.55–0.69)).

    HumansObesity and type 2 diabetes; compared with obesity management medications5 yearsn = 379,858

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery

Retinopathy

downin humans1HR 0.6

1 study
  1. Metabolic bariatric surgery is associated with retinopathy in humans (Obesity and type 2 diabetes; compared with obesity management medications) (3.6% versus 7.4%; -3.8 percentage points; HR 0.60 (95% CI 0.55–0.65)).

    HumansObesity and type 2 diabetes; compared with obesity management medications5 yearsn = 379,858

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery

More on Retinopathy

Nephropathy

downin humans1HR 0.55

1 study
  1. Metabolic bariatric surgery is associated with nephropathy in humans (Obesity and type 2 diabetes; compared with obesity management medications) (4.5% versus 8.3%; -3.8 percentage points; HR 0.55 (95% CI 0.52–0.60)).

    HumansObesity and type 2 diabetes; compared with obesity management medications5 yearsn = 379,858

    Obesity surgery linked to lower risks of complications and death

    The British journal of surgery

More on Nephropathy

Colorectal cancer

downin humans1

1 study
  1. Metabolic bariatric surgery is associated with colorectal cancer in humans (obesity; pooled retrospective matched cohorts) (IRR 0.72, 95% CI 0.59-0.88).

    Reviewobesity; pooled retrospective matched cohorts

More on Colorectal cancer

All 16

Funding

1 grant since 2024

National Institute of Diabetes and Digestive and Kidney Diseases$2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A human study associates metabolic bariatric surgery with improved maximal oxygen consumption despite reduced fat-free mass; reviews describe weight loss and link surgery to lower colorectal, breast and endometrial cancer incidence in people with obesity. Human results come from a single group, without opposing findings. All 4 findings come from papers declaring an interest of the intervention’s maker.

  2. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 2Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 1Sep 2026: 3Oct 2026: 5Nov 2026: 319 papers in 12 months
The British Journal of Surgery

Obesity surgery linked to lower risks of complications and death

Five-year rates of major heart and blood vessel events were 6.1% after surgery versus 8.1% after starting medication in adults with obesity and type 2 diabetes.Five-year rates of major heart and blood vessel events were 6.1% after surgery versus 8.1% after starting medication in adults with obesity and type 2 diabetes.

Cohort · 379,858 peopleObesity

See all 27 papers on metabolic bariatric surgery